Cochlear Ltd (ASX: COH) shares are finally showing signs of life, rising 2% to $129.63 and taking their five-day gain to 6%.
It's a welcome reprieve after the ASX healthcare stock was hammered 58% over the past 12 months. But with FY26 results due on 18 August, investors aren't exactly popping the champagne yet.
The last major update sent Cochlear shares into freefall. Could next week's results finally turn the story around?
Image source: Getty Images
Why did the stock get crushed?
The disaster began on 22 April. Cochlear slashed its FY26 underlying net profit guidance to $290 million to $330 million, down from $435 million to $460 million.
That's roughly a 30% cut at the midpoint, and the previous guidance had been reaffirmed just two months earlier.
Investors responded accordingly. Cochlear shares plunged 40.7% in a single session, marking the company's worst one-day decline on record.
Management blamed a cocktail of problems, including softer cochlear implant volumes across developed markets, hospital capacity constraints in Europe, weaker referral activity, and an unfavourable Australian dollar.
The Middle East conflict also resulted in cancelled orders and delayed deliveries.
So, what needs to go right now?
Three things investors need to see
First, Cochlear needs to land within its revised FY26 guidance range.
After such a brutal downgrade, credibility is arguably the company's most valuable asset. A result that misses again could seriously damage investor confidence.
Second, investors need to see whether Nexa is delivering. The smart cochlear implant is central to the bull case.
Cochlear hopes its product differentiation can help win market share, particularly in developed markets, while supporting higher average selling prices. Investors will want evidence that Nexa is gaining traction rather than another disruption like the one experienced during the first half.
Third, there's FY27 guidance.
Management previously flagged plans to reshape its cost base, creating capacity to invest in future growth. The market will be watching closely to see whether those plans can improve profitability without sacrificing investment.
Broker sentiment reflects the uncertainty
Analyst sentiment suggests investors remain cautious.
TradingView data shows the majority of brokers have a hold rating on Cochlear shares. The average price target is $127.60, implying around 1.5% downside from the current share price.
Morgans is even more conservative. The broker retained its hold rating but slashed its price target to $107.17 from $214.93.
That enormous target reduction highlights just how dramatically expectations have changed.
What's next for investors?
The 18 August result could be a pivotal moment. A result comfortably within guidance, encouraging Nexa momentum and constructive FY27 outlook could give Cochlear shares another leg higher.
But another earnings disappointment could quickly extinguish this tentative rebound.
After falling 58% in a year, the stock doesn't need perfection to surprise investors on the upside. It just needs to prove the worst is finally behind it.
